These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 36813089)

  • 41. Evaluation of food effect on the oral absorption of clarithromycin from immediate release tablet using physiological modelling.
    Radwan A; Jayyousi R; Shraim N; Zaid AN
    Biopharm Drug Dispos; 2019 Apr; 40(3-4):121-134. PubMed ID: 30891805
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Screening of Bioequivalent Extended-Release Formulations for Metformin by Principal Component Analysis and Convolution-Based IVIVC Approach.
    Zhang Y; Liu H; Tang MJ; Ho NJ; Shek TL; Yang Z; Zuo Z
    AAPS J; 2021 Mar; 23(2):38. PubMed ID: 33665728
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Application of a novel PhysioCell apparatus for biopredictive dissolution tests of oral immediate release formulations - A case study workflow for in vitro-in vivo predictions.
    Romański M; Staniszewska M; Paszkowska J; Dobosz J; Romanova S; Pieczuro J; Kątny M; Roznerska D; Szczepański J; Schraube M; Renn-Hojan M; Puk E; Hrem O; Garbacz G; Danielak D
    Int J Pharm; 2023 Jun; 641():123061. PubMed ID: 37211237
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Combining biorelevant in vitro and in silico tools to investigate the in vivo performance of the amorphous solid dispersion formulation of etravirine in the fed state.
    Litou C; Turner DB; Holmstock N; Ceulemans J; Box KJ; Kostewicz E; Kuentz M; Holm R; Dressman J
    Eur J Pharm Sci; 2020 Mar; 149():105297. PubMed ID: 32151705
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Improved drug transfer into brain tissue via the "nose-to-brain" approach using suspension or powder formulations based on the amorphous solid dispersion technique.
    Suwabe S; Tagami T; Ogawa K; Ozeki T
    Eur J Pharm Biopharm; 2023 Apr; 185():137-147. PubMed ID: 36842719
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Model-Based Analysis of Biopharmaceutic Experiments To Improve Mechanistic Oral Absorption Modeling: An Integrated in Vitro in Vivo Extrapolation Perspective Using Ketoconazole as a Model Drug.
    Pathak SM; Ruff A; Kostewicz ES; Patel N; Turner DB; Jamei M
    Mol Pharm; 2017 Dec; 14(12):4305-4320. PubMed ID: 28771009
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Amorphous solid dispersion with increased gastric solubility in tandem with oral disintegrating tablets: a successful approach to improve the bioavailability of atorvastatin.
    Salmani JM; Lv H; Asghar S; Zhou J
    Pharm Dev Technol; 2015 Jun; 20(4):465-72. PubMed ID: 24490758
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Validation of Dissolution Testing with Biorelevant Media: An OrBiTo Study.
    Mann J; Dressman J; Rosenblatt K; Ashworth L; Muenster U; Frank K; Hutchins P; Williams J; Klumpp L; Wielockx K; Berben P; Augustijns P; Holm R; Hofmann M; Patel S; Beato S; Ojala K; Tomaszewska I; Bruel JL; Butler J
    Mol Pharm; 2017 Dec; 14(12):4192-4201. PubMed ID: 28737403
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Development of nanoparticle-based orodispersible palatable pediatric formulations.
    Deng Y; Shen L; Yang Y; Shen J
    Int J Pharm; 2021 Mar; 596():120206. PubMed ID: 33493595
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Physiological Considerations and In Vitro Strategies for Evaluating the Influence of Food on Drug Release from Extended-Release Formulations.
    Koziolek M; Kostewicz E; Vertzoni M
    AAPS PharmSciTech; 2018 Oct; 19(7):2885-2897. PubMed ID: 30155808
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Ritonavir-PEG 8000 amorphous solid dispersions: in vitro and in vivo evaluations.
    Law D; Schmitt EA; Marsh KC; Everitt EA; Wang W; Fort JJ; Krill SL; Qiu Y
    J Pharm Sci; 2004 Mar; 93(3):563-70. PubMed ID: 14762895
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Efficient development of sorafenib tablets with improved oral bioavailability enabled by coprecipitated amorphous solid dispersion.
    Song S; Wang C; Wang S; Siegel RA; Sun CC
    Int J Pharm; 2021 Dec; 610():121216. PubMed ID: 34688849
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Melts of Octaacetyl Sucrose as Oral-Modified Release Dosage Forms for Delivery of Poorly Soluble Compound in Stable Amorphous Form.
    Haznar-Garbacz D; Kaminska E; Zakowiecki D; Lachmann M; Kaminski K; Garbacz G; Dorożyński P; Kulinowski P
    AAPS PharmSciTech; 2018 Feb; 19(2):951-960. PubMed ID: 29098644
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Oral Delivery of Niclosamide as an Amorphous Solid Dispersion That Generates Amorphous Nanoparticles during Dissolution.
    Jara MO; Warnken ZN; Sahakijpijarn S; Thakkar R; Kulkarni VR; Christensen DJ; Koleng JJ; Williams RO
    Pharmaceutics; 2022 Nov; 14(12):. PubMed ID: 36559062
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A mechanistic review on the dissolution phase behavior and supersaturation stabilization of amorphous solid dispersions.
    Ashwathy P; Anto AT; Sudheesh MS
    Drug Dev Ind Pharm; 2021 Jan; 47(1):1-11. PubMed ID: 33494623
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Evaluation of Dissolution in the Lower Intestine and Its Impact on the Absorption Process of High Dose Low Solubility Drugs.
    Georgaka D; Butler J; Kesisoglou F; Reppas C; Vertzoni M
    Mol Pharm; 2017 Dec; 14(12):4181-4191. PubMed ID: 28366005
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A pH-dilution method for estimation of biorelevant drug solubility along the gastrointestinal tract: application to physiologically based pharmacokinetic modeling.
    Gao Y; Carr RA; Spence JK; Wang WW; Turner TM; Lipari JM; Miller JM
    Mol Pharm; 2010 Oct; 7(5):1516-26. PubMed ID: 20715778
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Development of a Pediatric Mini-Tablet Formulation for Expedited Preclinical Studies.
    Lavan M; Wang X; McCain R; Jannasch A; Cooper B; Hostetler S; Byrn S; Knipp G
    AAPS PharmSciTech; 2021 Jan; 22(1):40. PubMed ID: 33417081
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Analysis of the enhanced oral bioavailability of fenofibrate lipid formulations in fasted humans using an in vitro-in silico-in vivo approach.
    Fei Y; Kostewicz ES; Sheu MT; Dressman JB
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):1274-84. PubMed ID: 23500116
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effects of Lipid Digestion and Drug Permeation/Re-Dissolution on Absorption of Orally Administered Ritonavir as Different Lipid-Based Formulations.
    Tanaka Y; Doi H; Katano T; Kasaoka S
    Eur J Pharm Sci; 2021 Feb; 157():105604. PubMed ID: 33098990
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.